CELLECTAR BIOSCIENCES INC
CLRBNASDAQTrading Snapshot
- Day Range
- $0.81 β $0.90
- 52-Week Range
- $0.76 β $4.70
- Volume (shares)
- 628
- Avg Volume (shares)
- β
- Shares Outstanding
- 10.0M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +203.3%
CELLECTAR BIOSCIENCES INC
CLRBAbout CELLECTAR BIOSCIENCES INC
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Cellectar Biosciences, Inc. (CLRB) Q3 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. ( CLRB ) Q3 2026 Earnings Call November 10, 2026 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor - Chief Operating Of

Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Presented updated data at the International Workshop for WaldenstrΓΆm Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in WaldenstrΓΆm macroglobulinemia (WM)

Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in WaldenstrΓΆm Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site a

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of can

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Durable Complete Response Achieved with Single Administration of Iopofosine I 131Β Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Ra

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for WaldenstrΓΆm Macroglobulinemia
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months